Jeannina Smith

Jeannina Smith


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
KLKathleen A. Linder
Kathleen A. Linder
CKChristopher Kovacs
Christopher Kovacs
KMKate M. Mullane
Kate M. Mullane
CWCameron Wolfe
Cameron Wolfe
NCNina M Clark
Nina M Clark
DKDaniel R. Kaul
Daniel R. Kaul

6 August 2013 in Current Infectious Disease Reports
Verified
Journal Article
Closed access
PDF file
JSJeannina Smith
Jeannina Smith
JRJames Riddell
James Riddell
CKCarol A. Kauffman
Carol A. Kauffman

29 June 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
MSMichael Scolarici
Michael Scolarici
MJMargaret Jorgenson
Margaret Jorgenson
CSChristopher Saddler
Christopher Saddler
JSJeannina Smith
Jeannina Smith
Invasive fungal infections (IFIs) are one of the most feared complications associated with liver transplantation, with high rates of morbidity and mortality. We discuss the most common invasive fungal infections in the setting of liver transplant, including Candida, Aspergillus, and Cryptococcal infections, and some less frequent but devastating mold infections. Further, we evaluate the use of prophylaxis to prevent invasive fungal infection in this population as a promising mechanism to reduce risks to patients after liver transplant.

27 May 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
MJMargaret R. Jorgenson
Margaret R. Jorgenson
JDJillian L. Descourouez
Jillian L. Descourouez
LSLucas T. Schulz
Lucas T. Schulz
KGKerry A. Goldrosen
Kerry A. Goldrosen
JRJohn P. Rice
John P. Rice
DMDidier Mandelbrot
Didier Mandelbrot
Classical stewardship efforts have targeted immunocompetent patients; however, appropriate use of antimicrobials in the immunocompromised host has become a target of interest. Cytomegalovirus (CMV) infection is one of the most common and significant complications after solid-organ transplant (SOT). The treatment of CMV requires a dual approach of antiviral drug therapy and reduction of immunosuppression for optimal outcomes. This dual approach to CMV management increases complexity and requires individualization of therapy to balance antiviral efficacy with the risk of allograft rejection. In this review, we focus on the development and implementation of CMV stewardship initiatives, as a component of antimicrobial stewardship in the immunocompromised host, to optimize the management of prevention and treatment of CMV in SOT recipients. These initiatives have the potential not only to improve judicious use of antivirals and prevent resistance but also to improve patient and graft survival given the interconnection between CMV infection and allograft function.

20 November 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
MJMargaret R Jorgenson
Margaret R Jorgenson
HKHanna Kleiboeker
Hanna Kleiboeker
NGNeetika Garg
Neetika Garg
SPSandesh Parajuli
Sandesh Parajuli
DMDidier Mandelbrot
Didier Mandelbrot
JSJeannina Smith
Jeannina Smith

26 July 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
MJMargaret R. Jorgenson
Margaret R. Jorgenson
JDJillian L. Descourouez
Jillian L. Descourouez
NGNeetika Garg
Neetika Garg
SPSandesh Parajuli
Sandesh Parajuli
DMDidier Mandelbrot
Didier Mandelbrot
JSJeannina Smith
Jeannina Smith